Giant Fold Gastritis Induced by Epoprostenol Infusion in Patients With Pulmonary Arterial Hypertension

被引：2

作者：

Miura, Yohei ^{[1
]}

Kataoka, Masaharu ^{[3
]}

Chiba, Tomohiro ^{[2
]}

Inami, Takumi ^{[1
]}

Yoshino, Hideaki ^{[1
]}

Satoh, Toru ^{[1
]}

机构：

[1] Kyorin Univ, Sch Med, Dept Internal Med 2, Div Cardiol, Tokyo, Japan

[2] Kyorin Univ, Sch Med, Dept Pathol, Tokyo, Japan

[3] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan

来源：

CIRCULATION JOURNAL | 2018年 / 82卷 / 10期

关键词：

Epoprostenol; Giant fold gastritis; Pulmonary arterial hypertension; Stomach barium examination; THERAPY;

D O I：

10.1253/circj.CJ-18-0349

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

引用

页码：2676 / 2677

页数：2

共 50 条

[31] Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Roos, Adrienne M.
Pasarikovski, Christopher
Kron, Amie T.
Granton, John T.
Lee, Peter
Thenganatt, John
Johnson, Sindhu R.
ARTHRITIS AND RHEUMATISM, 2013, 65 : S1099 - S1099
[32] Pulmonary arterial hypertension: Patient transition from epoprostenol to bosentan
Bshouty, Z
Da Ponte, FM
CHEST, 2003, 124 (04) : 89S - 89S
[33] Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
Timofeev, Julia
Ruiz, George
Fries, Melissa
Driggers, Rita W.
AJP REPORTS, 2013, 3 (02): : 71 - 74
[34] Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension
Sitbon, Olivier
Manes, Alessandra
Jais, Xavier
Pallazini, Massimiliano
Humbert, Marc
Presotto, Luis
de Nillette, Louis
Zaccardelli, Divid
Davis, Gillian
Jeff, Roger
Simonneau, Gerald
Galie, Naareno
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 49 (01) : 1 - 5
[35] Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
Sitbon, Olivier
Noordegraaf, Anton Vonk
EUROPEAN RESPIRATORY REVIEW, 2017, 26 (143):
[36] Epoprostenol Use for Pulmonary Arterial Hypertension in the Palliative Care Setting
Wozencraft, Colin P.
Coyne, Patrick J.
Grinnan, Daniel C.
Morel, Thomas D.
Muzevich, Katie M.
Smith, Thomas J.
JOURNAL OF PALLIATIVE MEDICINE, 2012, 15 (05) : 619 - 622
[37] Veletri® and Flolan® (Epoprostenol Sodium) in the Treatment of Pulmonary Arterial Hypertension
Chin, K. M.
Badesch, D. B.
Robbins, I. M.
Tapson, V. F.
Palevsky, H.
Kim, N. H.
Kawut, S. M.
Frost, A.
Benton, W. W.
Lemarie, J. C.
Bodin, F.
Rubin, L. J.
McLaughlin, V. V.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04): : S28 - S28
[38] Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension
Chin, Kelly M.
Channick, Richard N.
de Lemos, James A.
Kim, Nick H.
Torres, Fernando
Rubin, Lewis J.
CHEST, 2009, 135 (01) : 130 - 136
[39] Epoprostenol/tozinameranAcute exacerbation of pulmonary arterial hypertension and no therapeutic response
Reactions Weekly, 2024, 1993 (1) : 72 - 72
[40] EPOPROSTENOL RESCUE THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
Roos, A. M.
Pasarikovski, C. R.
Kron, A.
Granton, J. T.
Lee, P.
Thenganatt, J.
Johnson, S. R.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S86 - S87

← 1 2 3 4 5 →